Navigation Links
Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
Date:5/20/2008

Analysis Reveals Overall Survival Could be Extended if Patients Receive the

Most Effective Treatment Identified by ChemoFx

CHICAGO, May 20 /PRNewswire/ -- Precision Therapeutics Inc. announced today that the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlates with significantly longer overall survival (OS) in patients with primary ovarian cancer. Patients who received a treatment determined by ChemoFx to lead to the best tumor response had an overall survival 1.4 times longer than those receiving a treatment shown by ChemoFx to be non-responsive.

Despite the fact that all patients had the same type of tumor, 88 percent of patients exhibited varying degrees of response to different agents when evaluated by the cell-based test. The analysis also found that nearly two-thirds of patients' tumors were more responsive to a treatment identified by ChemoFx, than to the treatment they actually received. Based on these results, a mathematical model was created to estimate survival had patients been treated with a drug that ChemoFx identified as more likely to result in a greater tumor response. The analysis found that median OS could be extended as much as 23 to 38 months.

"These overall survival data demonstrate that the responsiveness to treatment established by this sensitivity assay in the laboratory setting, may in fact translate into meaningful clinical outcomes for patients," said Thomas J. Herzog, MD, director of gynecologic oncology at the Columbia University Medical Center and lead investigator of the study. "If these results are confirmed in current ongoing trials, this will be a significant step towards establishing individualized treatment strategies for patients who will require chemotherapy."

About the Study

Patients analyzed in the study had stage II-IV primary epithelial ovarian cancer that was tested by ChemoFx between 1997 an
'/>"/>

SOURCE Precision Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...  A $3 million grant from The Glenn Foundation ... to establish a national center of excellence in biogerontology ... Research at U-M will focus on exploiting and expanding ... of aging and postpone diseases in animal models. Researchers ... develop medications that may help people live longer, healthier ...
(Date:9/18/2014)... , Sept. 18, 2014  Neurotrope, Inc. (OTCQB: NTRP) ... , M.D., Ph.D. to the Company,s Board of Directors, ... fills a vacancy on the Board of seven members. ... and Corporate Governance Committee and a member of the ... a member of Neurotrope,s Scientific Advisory Board, a position ...
(Date:9/18/2014)... 18, 2014  Spring Bank Pharmaceuticals, Inc., a ... treatment of RNA viruses, today announced a research ... for animal testing of the Company,s lead compound, ... "Special Pathogens," against which currently there are no ... Spring Bank,s proprietary Small Molecule Nucleic Acid ...
Breaking Medicine Technology:$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 ... antidepressant can quickly alter the way brain cells communicate with ... Sept. 18 in Current Biology , are a ... antidepressants. Experts said the hope is to eventually be able ... from a drug -- and which people would fare better ...
(Date:9/18/2014)... 19, 2014 In 2003, ... Mission (Misión Barrio Adentro), which it hoped ... system (see Section 6.1.3.). In 2009, it ... Autonomous Service of Pharmaceutical Elaborations (Servicio Autónomo ... provides medicines at a cheaper rate than ...
(Date:9/18/2014)... 18, 2014 Ben Quirk, CEO of ... Jr. Leadership Award by the Savannah Science Seminar in ... wellness throughout the nation and especially in Savannah. , ... said Ben. “The Savannah Science Seminar is an amazing ... multiple generations have gone through the program,” he added. ...
(Date:9/18/2014)... convene a one-day conference at the Milken Institute School ... September 25, 2014 to discuss the Global Health Security ... purpose of this event is to invite discussion of ... years, including action plans to curtail the current deadly ... GHSA, international organizations and more than 50 countries have ...
(Date:9/18/2014)... N.C. Dangerous new pathogens such as the Ebola ... ancient scourges such as the bubonic plague are still ... responds to infections. , In a study published online ... researchers at Duke Medicine and Duke-NUS Graduate Medical School ... bubonic plague hitchhike on immune cells in the lymph ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2Health News:New insights on an ancient plague could improve treatments for infections 2
... Orissa government has ordered administrations of all 30 districts to ... three days.// ,The officials were Thursday asked to ... senior health department official. ,These would then be ... government does not have testing facilities to confirm the presence ...
... safety lawyer, writes about why it is essential for us ... that there is a major defect in the food safety ... people affected or even killed by contaminated food products from ... it prevents our society from knowing the source of our ...
... of NSAID by women in their first trimester could ... ,Non-steroidal anti-inflammatory drugs, NSAIDs, Cardiac septal defects, Journal ... Congenital abnormality, Diabetes ,Women who take non-steroidal ... more likely to give birth to babies with congenital ...
... say that a commonly used HIV drug may be useful ... be used in prevention of the cancer and could be ... and his colleagues said that such a cream could prove ... lesions. However no clinical trials have begun as yet. ...
... hundreds of resident doctors in Delhi who had gone on ... agitation //for the next three months with the reservation bill ... the parliament has referred the reservation bill to the standing ... being. The bill will be placed in the floor of ...
... the University of Pennsylvania have disclosed that a specific ... of changing into bone, muscle, neurons or other// types ... environment. , ,The researchers found that ... bone marrow, are soliciting tangible clues from their local ...
Cached Medicine News:Health News:Importance of knowing the source of our food 2Health News:NSAIDs In First trimester Linked To Congenital Anomalies In Babies 2Health News:Medicos Suspends Anti-quota Stir 2Health News:Adult stem cells are sensitive to responses from the environment 2
85 left angled suture passer....
45 right angled suture passer....
... a fully-absorbable soft tissue anchor constructed ... and provides fixation strength comparable to ... anchor retains strength throughout the soft ... leaving no permanent foreign material presence. ...
... a fully absorbable soft tissue anchor designed ... dynamic engagement into cancellous bone, its broad ... tip length provide significant resistance to pullout ... material anchor construction provides the benefits of ...
Medicine Products: